Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lenka Štorkánová"'
Autor:
Hana Štorkánová, Lenka Štorkánová, Adéla Navrátilová, Viktor Bečvář, Hana Hulejová, Sabína Oreská, Barbora Heřmánková, Maja Špiritović, Radim Bečvář, Karel Pavelka, Jiří Vencovský, Jörg H. W. Distler, Ladislav Šenolt, Michal Tomčík
Publikováno v:
Biomedicines, Vol 11, Iss 10, p 2736 (2023)
In the original publication [...]
Externí odkaz:
https://doaj.org/article/5cb0e2c586d14d5590ea13801e94857f
Autor:
Hana Štorkánová, Lenka Štorkánová, Adéla Navrátilová, Viktor Bečvář, Hana Hulejová, Sabína Oreská, Barbora Heřmánková, Maja Špiritović, Radim Bečvář, Karel Pavelka, Jiří Vencovský, Jörg H. W. Distler, Ladislav Šenolt, Michal Tomčík
Publikováno v:
Biomedicines, Vol 9, Iss 6, p 650 (2021)
Our previous study demonstrated that heat shock protein 90 (Hsp90) is overexpressed in the involved skin of patients with systemic sclerosis (SSc) and in experimental dermal fibrosis. Pharmacological inhibition of Hsp90 prevented the stimulatory effe
Externí odkaz:
https://doaj.org/article/4ff5b7e455b94a139f7f9a2d3de9e59d
Autor:
Sabína Oreská, Adela Navrátilová, Radim Bečvář, Maja Špiritović, Jiří Vencovský, Hana Hulejová, Hana Štorkánová, B. Heřmánková, Viktor Bečvář, Jörg H W Distler, Karel Pavelka, Lenka Štorkánová, Michal Tomcik, Ladislav Šenolt
Publikováno v:
Biomedicines
Volume 9
Issue 6
Biomedicines, Vol 9, Iss 650, p 650 (2021)
Volume 9
Issue 6
Biomedicines, Vol 9, Iss 650, p 650 (2021)
Our previous study demonstrated that heat shock protein 90 (Hsp90) is overexpressed in the involved skin of patients with systemic sclerosis (SSc) and in experimental dermal fibrosis. Pharmacological inhibition of Hsp90 prevented the stimulatory effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bab1677dc717a1d1386e3df954e9637
http://europepmc.org/articles/PMC8226767
http://europepmc.org/articles/PMC8226767
Autor:
Barbora Szotáková, Vladimír Wsól, Martina Dvorščaková, Luděk Šišpera, Lenka Štorkánová, V. Baliharová, Lenka Skálová
Publikováno v:
The Journal of pharmacy and pharmacology. 56(2)
The promising new drug quinlukast, 4-(4-(quinoline-2′-yl-methoxy)phenylsulphanyl)benzoic acid (VÚFB 19363), is under investigation for its anti-inflammatory and anti-asthmatic effects. The main metabolite of quinlukast identified in incubations of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c99322b08b48f5d6aa19f61fa1eddcd1
https://pubmed.ncbi.nlm.nih.gov/15005879
https://pubmed.ncbi.nlm.nih.gov/15005879